Compare MGRX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRX | IMNN |
|---|---|---|
| Founded | 2021 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 7.9M |
| IPO Year | 2023 | 2000 |
| Metric | MGRX | IMNN |
|---|---|---|
| Price | $0.26 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 522.9K | 98.7K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $456,021.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.96 |
| 52 Week High | $2.50 | $4.93 |
| Indicator | MGRX | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 30.21 | 50.77 |
| Support Level | N/A | $0.96 |
| Resistance Level | $0.49 | $1.59 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 2.60 | 73.61 |
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.